Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07823348 | JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer | not yet recruiting | Phase 3 | 560 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02381561 | Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy | active not recruiting | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 |
| NCT02523443 | Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection | active not recruiting | Phase 3 | 231 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04165772 | Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | recruiting | Phase 2 | 212 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | recruiting | Phase 1 / Phase 2 | 300 | PMV Pharmaceuticals, IncINDUSTRY | 9 | Sep 15, 2026 | clinicaltrials |
| NCT05438459 | GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites | recruiting | Phase 1 / Phase 2 | 176 | Kyushu UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05692596 | The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics | active not recruiting | — | 317 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05854498 | Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer | recruiting | Phase 2 | 50 | University of Wisconsin, MadisonOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05994001 | Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody | active not recruiting | Phase 1 / Phase 2 | 78 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06007846 | A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer | recruiting | Phase 2 / Phase 3 | 12 | Inova Health Care ServicesOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06146946 | Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H) | recruiting | N/A | 1,384 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06246344 | Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer | active not recruiting | Phase 3 | 128 | Shandong Cancer Hospital and InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06263088 | EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. | recruiting | N/A | 200 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06412510 | Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT | active not recruiting | Phase 1 / Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06423963 | Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer | recruiting | N/A | 26 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06633224 | Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT | recruiting | — | 125 | University of California, San FranciscoOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06687603 | Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms | recruiting | N/A | 800 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06730373 | First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) | recruiting | Phase 2 | 110 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06976710 | PRIORITY-CONNECT 2 Trial(PC2) | recruiting | N/A | 564 | Surgical Outcomes Research Centre (SOuRCe)NETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07044362 | Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis | recruiting | N/A | 100 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07220018 | Colorectal Cancer Screening in the Homeless | recruiting | N/A | 588 | George Washington UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07255001 | Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life(PanFit) | recruiting | N/A | 50 | British Columbia Cancer AgencyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07284849 | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | recruiting | Phase 3 | 700 | Incyte CorporationINDUSTRY | 22 | Sep 15, 2026 | clinicaltrials |
| NCT07341737 | SL-28 for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 60 | Second Life TherapeuticsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07367516 | Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 105 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07429487 | Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer(WATCH AND ACT) | recruiting | N/A | 98 | Centre Antoine LacassagneOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07500259 | Exploratory Clinical Evaluation of Personalized Functional Profiling in GI Tumors: Predicting Drug Response in CRC and PDAC(COLOPan) | recruiting | — | 188 | Luxembourg Institute of HealthOTHER_GOV | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07540832 | A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC | not yet recruiting | Phase 1 / Phase 2 | 80 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07702292 | [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 106 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07769853 | Iparomlimab and Tuvonralimab Combined With Chemotherapy and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Rectal Cancer(IT-CABLE) | not yet recruiting | N/A | 56 | Zhejiang UniversityOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07775209 | Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma(SSIBLING) | enrolling by invitation | Phase 2 | 24 | University of Vermont Medical CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07776080 | Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07815392 | Preoperative Frailty and Postoperative Outcomes in Older Patients Undergoing Surgery for Gastrointestinal Cancer | recruiting | — | 100 | Van Training and Research HospitalOTHER_GOV | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819604 | Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 85 | Xijing HospitalOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07820644 | A Cohort Study (Risk Prediction of HCC in Patients With Chronic Liver Disease) | recruiting | — | 15,000 | Cai QingxianOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT01313442 | Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer | recruiting | — | 550 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02782949 | Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia | active not recruiting | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 2 | Sep 14, 2026 | clinicaltrials |
| NCT02869802 | Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis(PanGen) | recruiting | — | 190 | British Columbia Cancer AgencyOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03151564 | Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques | active not recruiting | N/A | 146 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03533582 | Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | active not recruiting | Phase 3 | 537 | Children's Oncology GroupNETWORK | 6 | Sep 14, 2026 | clinicaltrials |
| NCT04115631 | A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | active not recruiting | Phase 2 | 360 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04166318 | Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study | active not recruiting | Phase 2 | 252 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04248452 | Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body | active not recruiting | Phase 3 | 314 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04380545 | Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer | recruiting | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04559139 | Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer | active not recruiting | Phase 2 / Phase 3 | 186 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
Data updated 14 days agoSource updated Sep 16, 2026source: clinicaltrials